Proactive Investors - Run By Investors For Investors

Instem upbeat though clinical headwinds persist

Recurring revenue and SaaS [pay-as–you-go] software revenue grew 21% and 38%
picture of pills
New US monitoring protocols have helped Instem

The provider of IT solutions to the global early development healthcare market Instem Plc (LON:INS) notched up big increases in recurring revenues in the year just ended.

“Recurring revenue and SaaS [pay-as–you-go] software revenue growth of 21% and 38%, respectively, were particularly pleasing,” said Phil Reason, chief executive.

The one weak spot was the clinical arm, where Instem had already flagged the performance was going to be well short of targets, but Reason expects sales growth elsewhere to offset any further weakness in 2017.

WATCH: Instem boss "very excited" about SEND opportunities ...

In particular, he highlighted growing momentum at the KnowledgeScan big data analytics and insights service, introduced in 2016, while there would be full year contributions from the Samarind and Notocord acquisitions.

Changes to the way US regulator the logs and monitors drugs in trials have also helped Instem and the FDA regulations will drive further market growth. 

Even so, there will be an investment cost will be in the short term and Reason said  “near term profit will be significantly reduced by this and other investment across the group,” but  he remains upbeat over the longer term.

Profits in 2016 were £23,000 (£361,000 loss), though on an adjusted basis there was a dip to £700,000 from £1.7mln.

View full INS profile View Profile

Instem Plc Timeline

Big Picture
September 19 2016

Related Articles

House sale
January 18 2017
The real estate listings market has long needed an overhaul; RESAAS provides it.
RSI International Systems looking to scale up with its innovative hotel property management system
July 18 2017
RoomKeyPMS is the product at the heart of Toronto-listed RSI International Systems Inc's business
Care home worker and elderly person
August 16 2017
cloudBuy is focusing on big projects such as a web site that could revolutionise how personal health budgets are spent, and its collaboration with Asian bank UOB

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use